Type 2 Diabetes

>

Latest News

Credit: US Food and Drug Administration
Semaglutide (Wegovy) Receives FDA Label Expansion to Include Cardiovascular Risk Reduction

March 8th 2024

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

Stock imagery of a body weight scale. | Credit: iStock
Novo Nordisk Delivers Updates on Development of Semaglutide, CagriSema, Amycretin, and More

March 7th 2024

Endocrinology month in review February 2024 thumbnail
Endocrinology Month in Review: February 2024

March 6th 2024

Kidney albuminuria | Credit: Fotolia
HCV Antibody Seropositivity Linked to Increased Albuminuria in Patients with Type 2 Diabetes

March 6th 2024

Shih-Chieh Shao, RPh, PhD | Image Credit: ResearchGate
SGLT2 Inhibitor Use Lowers Anemia Risk in Patients with Diabetes, CKD

March 5th 2024

Video Series
Video Interviews
Podcasts
W. Timothy Garvey, MD | Credit: UAB Medicine
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
Julie Heverly | Credit: DiaTribe
Thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of Diana Isaacs, PharmD, and Natalie Bellini, DNP
W. Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Cari Berget, RN, MPH | Credit: PANTHER Program

More News

© 2024 MJH Life Sciences

All rights reserved.